Background: Prevalence of fluoroquinolone-resistant Klebsiella oxytoca has been reported worldwide. Methods: We recovered ten clinical K. oxytoca isolates from patients with acute cystitis, asymptomatic bacteriuria or acute bacillary diarrhea in Japan. Out of ten isolates, one fluoroquinolone-susceptible isolate was included as a control. Fluoroquinolone resistance was characterized genetically by PCR and DNA sequencing methods. Outer membrane protein (OMP) profiles were determined by SDS-PAGE. Results: In nine clinical isolates of levofloxacin-resistant K. oxytoca, nucleotide sequences in the quinolone-resistance-determining regions showed amino acid mutations such as Thr83Ile and Asp87Gly in GyrA and Ser80Ile in ParC. Combined effects of reduced 36-kDa OMP production and amino acid mutations in GyrA and ParC were shown by two K. oxytoca isolates exhibiting higher minimum inhibitory concentrations for fluoroquinolones than other fluoroquinolone-resistant isolates. Conclusions: In clinical K. oxytoca isolates, the various mechanisms of fluoroquinolone resistance may include reduced 36-kDa OMP production as well as GyrA and ParC mutations.

Keywords:
Fluoroquinolone resistance, GyrA, Klebsiella oxytoca, Outer membrane protein, ParC
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.